Albumin, being the most abundant serum protein, has the
potential
to significantly enhance the physicochemical properties of therapeutic
payloads, thereby improving their pharmacological effects. Apart from
its passive transport via the enhanced permeability and retention
effect, albumin can actively accumulate in tumor microenvironments
or inflammatory tissues via receptor-mediated processes. This unique
property makes albumin a promising scaffold for targeted drug delivery.
This review focuses on exploring different delivery strategies that
combine albumin with drug payloads to achieve targeted therapy for
inflammatory diseases. Also, albumin-derived therapeutic products
on the market or undergoing clinical trials in the past decade have
been summarized to gain insight into the future development of albumin-based
drug delivery systems. Given the involvement of inflammation in numerous
diseases, drug delivery systems utilizing albumin demonstrate remarkable
advantages, including enhanced properties, improved in vivo behavior and efficacy. Albumin-based drug delivery systems have
been demonstrated in clinical trials, while more advanced strategies
for improving the capacity of drug delivery systems with the help
of albumin remain to be discovered. This could pave the way for biomedical
applications in more effective and precise treatments.